REDCURE Registry for Chronic Kidney Disease (CKD) Anemia
ConditionCKD Anemia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNabiqasim Industries (Pvt) Ltd
About this trial
A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat
Eligibility criteria
Qualifiers
Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)
Patients on hemodialysis (HD) or peritoneal dialysis (PD)
Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent
Disqualifiers
Acute Kidney Injury (AKI) without underlying chronicity
Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
Refusal or inability to provide consent
Current enrollment in an interventional trial that restricts real-world data collection
Trial design
Treatments tested in this trial
- Daprodustat
Treatment groups
384 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov